Google
×
Aug 1, 2011 · Long-term outcome with respect to progression-free survival, overall survival, and relapse rate is superior after auto-allo compared with auto only.
Progression-free survival at 60 months was significantly better with auto-allo than with allo alone (35% v 18%; P = .001), as was the risk of death and of ...
Jun 20, 2013 · Tandem autologous/reduced-intensity allogeneic transplantation is superior to autologous transplantation alone in multiple myeloma. Abstract.
Jun 20, 2013 · At 96 months progression-free survival (PFS) and overall survival (OS) were 22% and 49% vs 12% (P = .027) and 36% (P = .030) with auto/RICallo ...
Long-term follow-up of auto-auto versus auto-allo in newly diagnosed multiple myeloma patients confirms significant and durable reduction in risk of relapse ...
People also ask
Feb 1, 2019 · Our study showed that tandem autologous/minimal intensity allogeneic HCT for MM was safe and characterized by low acute and long-term toxicities.
Long-term follow-up of auto-auto versus auto-allo in newly diagnosed multiple myeloma patients confirms significant and durable reduction in risk of relapse.
In comparison to tandem-auto-SCT, patients assigned to auto-allo-SCT exhibited a higher risk of transplant-related mortality (TRM) (11.9% vs. 4.1%) and non- ...
Aug 1, 2011 · Allogeneic Stem-Cell Transplantation Versus Autologous. Transplantation in Myeloma: Long-Term Follow-Up. Bo Björkstrand, Simona Iacobelli, Ute ...
Jun 20, 2013 · Long-term outcome in patients with multiple myeloma was better with auto/RICallo as compared with auto only and the auto/RICallo approach seemed to overcome ...